Inhibition of Leukemic Cell Growth by the Protein Kinase C Activator Bryostatin 1 Correlates with the Dephosphorylation of Cyclin-dependent Kinase 2

Clement Asiedu, Joseph Biggs, Andrew S. Kraft, Michael Lilly

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

Bryostatin 1 is a natural antineoplastic agent that activates protein kinase C. Treatment of U937 human leukemic cells with bryostatin 1 caused a 60% reduction in cell growth, whereas another protein kinase C activator, phorbol myristate acetate (PMA), completely inhibited U937 cell growth. Both bryostatin 1 and PMA induced inhibition of cyclin-dependent kinase 2 (cdk2) activity. The first phase of cdk2 inhibition correlated with the transient induction of p21, a known inhibitor of cdk2. In contrast, the second phase of cdk2 inhibition correlated with the dephosphorylation of cdk2 on threonine-160, which must be phosphorylated for cdk2 activity. The level of growth inhibition induced by these two compounds correlated with the degree of cdk2 dephosphorylation as follows: bryostatin 1, 60%; PMA, 100%.

Original languageEnglish (US)
Pages (from-to)3716-3720
Number of pages5
JournalCancer Research
Volume55
Issue number17
StatePublished - Sep 1 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibition of Leukemic Cell Growth by the Protein Kinase C Activator Bryostatin 1 Correlates with the Dephosphorylation of Cyclin-dependent Kinase 2'. Together they form a unique fingerprint.

  • Cite this